CEDAR KNOLLS, N.J.,
Dec. 6, 2017 /PRNewswire/
-- MYOS RENS Technology Inc. ("MYOS" or "the Company")
(Nasdaq: MYOS), has entered into a research agreement with the
University of California, Berkeley's
Department of Nutritional Sciences & Toxicology. The
study will look into the effects of Fortetropin® on increasing the
fractional rate of skeletal muscle protein synthesis in men and
women between 60 and 75 years old. Fortetropin®, owned by
MYOS RENS, a bionutrition company, is a natural food product that
helps build lean muscle in conjunction with resistance
training. The Principal Investigator for this clinical study
will be William J. Evans, PhD,
Adjunct Professor of Human Nutrition at the Department of
Nutritional Sciences & Toxicology at the University of California, Berkeley campus.
Professor Evans, a leading authority in muscle health research,
will coordinate the activities of a multi-disciplinary team of
scientists and physicians.
Fortetropin® is the Company's proprietary all-natural food
ingredient clinically shown to increase muscle size, lean body mass
and strength as part of resistance training. Fortetropin® is
made from fertilized chicken egg yolks using a proprietary process
that retains the biological integrity and bioactivity of the
product. In an animal study, Fortetropin® was shown to
up-regulate muscle building and down-regulate muscle destruction
pathways.
In this randomized, double-blind, placebo-controlled clinical
study, 20 subjects, men and women 60 – 75 years of age, will take
either Fortetropin® or placebo for 21 days along with daily doses
of a heavy water tracer. After 21 days, a microbiopsy will be
collected from each subject to determine the fractional rate of
muscle protein synthesis. MYOS anticipates the clinical study
will be completed and its results announced in the second half of
2018.
"This study represents part of MYOS' strategy to leverage
cutting edge technologies that have been developed by pioneers in
the field of muscle health to better understand the potential
benefits of Fortetropin® across many broad areas. Favorable
results from this study may help to support individuals who want to
maintain optimal muscle health as they age," said Joseph Mannello, CEO of MYOS.
Professor Evans said, "My colleagues and I are excited about
this research. Maintaining good muscle health is vital to
enjoying a good quality of life as we age. It is well
understood that people lose muscle as they age. Scientists
believe that reduced rates of muscle protein synthesis play a
primary role in age-related muscle loss. Positive results
from this clinical study may represent an exciting advance in
addressing age-related muscle loss in the elderly population."
About MYOS RENS Technology Inc.
MYOS RENS Technology Inc. (MYOS), "The Muscle Company™", is a
Cedar Knolls, NJ-based
bionutrition company that develops and markets products that
improve muscle health and performance. MYOS is the owner of
Fortetropin®, the world's first clinically-demonstrated myostatin
reducer. Myostatin is a natural regulatory protein, which inhibits
muscle growth. Fortetropin® is a fertilized egg yolk based product
manufactured via a proprietary process to retain and optimize its
biological activity. Fortetropin® has been clinically shown to
increase muscle size and lean body mass in conjunction with
resistance training. MYOS believes Fortetropin® has the potential
to redefine existing standards of physical health and wellness. For
more information, please visit www.MYOSRENS.com.
Forward-Looking Statements
Any statements in
this release that are not historical facts are forward-looking
statements. Actual results may differ materially from those
projected or implied in any forward-looking statements. Such
statements involve risks and uncertainties, including but not
limited to those relating to product and customer demand, market
acceptance of our products, the ability to create new products
through research and development, the successful results of
strategic initiatives, the successful launch of our products,
including Qurr® products, the success of our research and
development, including the clinical study described above, the
results of the clinical evaluation of Fortetropin® and its effects,
the ability to enter into new partnership opportunities and the
success of our existing partnerships, the ability to generate the
forecasted revenue stream and cash flow from sales of our products,
the ability to continue increasing our revenue and gross profit
margins, the ability to achieve a sustainable, profitable business,
the effect of economic conditions, the ability to protect our
intellectual property rights, competition from other providers and
products, the continued listing of our securities on the Nasdaq
Stock Market, risks in product development, our ability to raise
capital to fund continuing operations, and other factors discussed
from time to time in our filings with the Securities and
Exchange Commission. We undertake no obligation to update or revise
any forward-looking statement for events or circumstances after
the date on which such statement is made except as required by
law.
These statements have not been evaluated by the Food and Drug
Administration. Our products are not intended to diagnose, treat,
cure or prevent any disease.
Investor Relations:
Porter LeVay & Rose
Michael Porter, President
Phone: 212-564-4700
Email: MYOS@plrinvest.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/myos-rens-technology-enters-into-research-agreement-with-university-of-california-berkeley-to-study-effects-of-fortetropin-on-skeletal-muscle-protein-synthetic-rate-in-older-men-and-women-300567420.html
SOURCE MYOS RENS Technology